Renalytix (LON:RENX) Shares Down 18% – Should You Sell?

Renalytix Plc (LON:RENX)’s stock price dropped 18% on Wednesday . The stock traded as low as GBX 2.05 and last traded at GBX 2.05. Approximately 1,699,937 shares were traded during trading, an increase of 82% from the average daily volume of 934,569 shares. The stock had previously closed at GBX 2.50.

Renalytix Price Performance

The company has a debt-to-equity ratio of -599.34, a quick ratio of 2.42 and a current ratio of 2.43. The firm has a market capitalization of £10.79 million, a price-to-earnings ratio of -0.35 and a beta of 1.80. The company has a 50-day moving average of GBX 4.22 and a 200-day moving average of GBX 6.25.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).